Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy

Journal of Infection and Chemotherapy

Volumn 17, Issue 3, 2011, Pages 382-387

  Takahashi, Yoshiko ^a   Takesue, Yoshio ^a   Nakajima, Kazuhiko ^a   Ichiki, Kaoru ^a   Tsuchida, Toshie ^a   Tatsumi, Sumiyo ^a   Ishihara, Mika ^a   Ikeuchi, Hiroki ^b   Uchino, Motoi ^b  

^a HYOGO COLLEGE OF MEDICINE HOSPITAL   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Adverse effect; Linezolid; Renal insufficiency; Risk factor; Thrombocytopenia

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CREATININE; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDIASTINITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PROSTHESIS INFECTION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SEPTIC SHOCK; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 80051594912     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-010-0182-1     Document Type: Article

References (21)

1. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillinresistant Staphylococcus aureus infection. Clin Infect Dis. 2002;34:1481-90. (Pubitemid 34553708)
2. Perry CM, Javis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs. 2001;61:525-51. (Pubitemid 32368068)
3. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138:135-42.
4. Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother. 2003;37:517-20. (Pubitemid 36389660)
5. Whitehouse T, Cepeda JA, Shulman R, Aarons L, Nalda-Molina R, Tobin C, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother. 2005;55:333-40. (Pubitemid 40425458)
6. Steinmetz MP, Vogelbaum MA, De Georgia MA, Andrefsky JC, Isada C. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Crit Care Med. 2001;29:2383-5. (Pubitemid 34038174)
7. Senneville E, Legout L, Valette M, Yazdanpanah Y, Giraud F, Beltrand E, et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother. 2004;54:798-802. (Pubitemid 39386734)
8. De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006;42:1111-7.
9. Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR, Thomasco LM, et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell. 2007;26:393-402. (Pubitemid 46687101)
10. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46:2723-6. (Pubitemid 34793498)
11. Wu VC, Wang YT, Wang CY, Tsai IJ, Wu KD, Hwang JJ, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42:66-72.
12. Lin YH, Wu VC, Tsai IJ, Ho YL, Hwang JJ, Tsau YK, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28:345-51.
13. Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34:695-8. (Pubitemid 34165334)
14. Orrick JJ, Johns T, Janelle J, Ramphal R. Thrombocytopenia secondary to linezolid administration: what is the risk? Clin Infect Dis. 2002;35:348-9. (Pubitemid 34800291)
15. Babcock HM, Fraser V. Clinical experience with linezolid: a case series of 53 patients. Infect Dis Clin Pract (Baltim Md). 2002;11:198-204. (Pubitemid 36042557)
16. Grau S, Morales-Molina JA, Mateu-de Antonio J, Marín-Casino M, Alvarez-Lerma F. Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia. J Antimicrob Chemother. 2005;56:440-1. (Pubitemid 41158548)
17. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrugresistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36:159-68. (Pubitemid 36143412)
18. Soriano A, Ortega M, Garcia S, Peñarroja G, Bové A, Marcos M, et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother. 2007;51:2559-63. (Pubitemid 47047337)
19. Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O'Grady M, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47:2775-80. (Pubitemid 37040247)
20. Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010;36:179-81.
21. Beringer P, Nguyen M, Hoem N, Louie S, Gill M, Gurevitch M, et al. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother. 2005;49:3676-81. (Pubitemid 41233017)